AR088028A1 - Proteinas h5, de h5n1 para un uso medicinal - Google Patents
Proteinas h5, de h5n1 para un uso medicinalInfo
- Publication number
- AR088028A1 AR088028A1 ARP120102979A ARP120102979A AR088028A1 AR 088028 A1 AR088028 A1 AR 088028A1 AR P120102979 A ARP120102979 A AR P120102979A AR P120102979 A ARP120102979 A AR P120102979A AR 088028 A1 AR088028 A1 AR 088028A1
- Authority
- AR
- Argentina
- Prior art keywords
- virus
- clade
- protein
- combination
- seq
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 11
- 102000004169 proteins and genes Human genes 0.000 title abstract 11
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 10
- 238000000034 method Methods 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 101710154606 Hemagglutinin Proteins 0.000 abstract 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 4
- 101710176177 Protein A56 Proteins 0.000 abstract 4
- 239000000185 hemagglutinin Substances 0.000 abstract 4
- 230000005764 inhibitory process Effects 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 238000011282 treatment Methods 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 241000711404 Avian avulavirus 1 Species 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523772P | 2011-08-15 | 2011-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088028A1 true AR088028A1 (es) | 2014-05-07 |
Family
ID=46651534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102979A AR088028A1 (es) | 2011-08-15 | 2012-08-14 | Proteinas h5, de h5n1 para un uso medicinal |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20140199337A1 (enExample) |
| EP (1) | EP2744514B1 (enExample) |
| JP (1) | JP2014527526A (enExample) |
| KR (1) | KR101986071B1 (enExample) |
| CN (1) | CN104144699A (enExample) |
| AR (1) | AR088028A1 (enExample) |
| AU (1) | AU2012296834A1 (enExample) |
| BR (1) | BR112014003278A2 (enExample) |
| CA (1) | CA2845040A1 (enExample) |
| CO (1) | CO7020855A2 (enExample) |
| EA (1) | EA201400235A1 (enExample) |
| ES (1) | ES2765073T3 (enExample) |
| MX (1) | MX363464B (enExample) |
| PH (1) | PH12014500369A1 (enExample) |
| WO (1) | WO2013024113A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
| ES2689878T3 (es) * | 2013-02-21 | 2018-11-16 | Boehringer Ingelheim Vetmedica Gmbh | Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento |
| KR102173999B1 (ko) | 2014-07-17 | 2020-11-04 | 주식회사 만도 | 차량 통신 제어장치 및 방법 |
| EA201991041A1 (ru) | 2016-11-03 | 2019-11-29 | Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения | |
| WO2020093984A1 (en) * | 2018-11-06 | 2020-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Immunogenic composition against avian influenza virus h5 subtype |
| KR20250080034A (ko) | 2023-11-27 | 2025-06-05 | 주식회사 카브 | 고병원성 조류인플루엔자 바이러스 및 뉴캐슬병 바이러스의 예방 및 백신 조성물 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US382425A (en) | 1888-05-08 | Brandt | ||
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4552758A (en) | 1983-12-20 | 1985-11-12 | St. Jude Children's Research Hospital | Human use of avian-human reassortants as vaccines for influenza A virus |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| IE872748L (en) | 1986-10-16 | 1988-04-16 | Arjomari Europ | Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| EP0386185A1 (fr) | 1988-07-29 | 1990-09-12 | IntraCel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
| CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
| DE69034078T2 (de) | 1989-03-21 | 2004-04-01 | Vical, Inc., San Diego | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
| US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| US5690938A (en) | 1989-07-07 | 1997-11-25 | Oravax, Inc. | Oral immunization with multiple particulate antigen delivery system |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| GB9001766D0 (en) | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
| DK0528859T3 (da) | 1990-04-24 | 1998-09-14 | Flustat Pty Ltd | Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer |
| AU672359B2 (en) | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
| EP0561034B1 (en) | 1991-08-26 | 1999-06-09 | IMMUNO Aktiengesellschaft | Direct molecular cloning of a modified chordopox virus genome |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| US5807722A (en) | 1992-10-30 | 1998-09-15 | Bioengineering Resources, Inc. | Biological production of acetic acid from waste gases with Clostridium ljungdahlii |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| IL108915A0 (en) | 1993-03-18 | 1994-06-24 | Merck & Co Inc | Polynucleotide vaccine against influenza virus |
| FR2711670B1 (fr) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
| ATE475668T1 (de) | 1994-01-27 | 2010-08-15 | Univ Massachusetts Medical | Immunisierung durch impfung von dns transkriptionseinheit |
| CA2188447C (en) | 1994-04-29 | 2002-10-22 | Falko-Gunter Falkner | Recombinant poxviruses with foreign polynucleotides in essential regions |
| US5928913A (en) | 1995-03-23 | 1999-07-27 | Efstathiou; Stacey | Vectors for gene delivery |
| WO1998000166A1 (en) | 1996-07-03 | 1998-01-08 | Merial, Inc. | Recombinant canine adenovirus (cav) containing exogenous dna |
| US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
| US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| US6951754B2 (en) | 2000-04-28 | 2005-10-04 | St. Jude Children's Research Hospital | DNA transfection system for the generation of infectious influenza virus |
| AU2002218742A1 (en) | 2000-07-11 | 2002-01-21 | Johns Hopkins University | Application of photochemotherapy for the treatment of cardiac arrhythmias |
| JPWO2002062381A1 (ja) | 2001-02-05 | 2004-06-03 | 久光製薬株式会社 | バキュロウイルスベクターワクチン |
| CA2456034A1 (en) | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
| US20040146533A1 (en) * | 2002-08-27 | 2004-07-29 | Miller Timothy J. | Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry |
| US7566458B2 (en) | 2003-06-16 | 2009-07-28 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase variants |
| US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
| US20080254065A1 (en) | 2004-03-09 | 2008-10-16 | Chiron Corporation | Influenza Virus Vaccines |
| AU2005248375B2 (en) | 2004-05-25 | 2010-12-16 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase varians |
| CN1748795A (zh) | 2004-09-17 | 2006-03-22 | 金宁一 | 多价禽流感重组活载体疫苗 |
| KR20080052509A (ko) | 2005-04-11 | 2008-06-11 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 | 유행성 독감 바이러스에 대한 백신 |
| US7871626B2 (en) | 2005-08-04 | 2011-01-18 | St. Jude Children's Research Hospital | Modified influenza virus for monitoring and improving vaccine efficiency |
| AU2006304640B2 (en) | 2005-10-18 | 2012-10-11 | Novavax, Inc. | Functional influenza virus like particles (VLPs) |
| US8883123B2 (en) * | 2005-10-28 | 2014-11-11 | Boehringer Ingleheim Vetmedica, Inc. | Use of vaccines for the treatment/prevention of the transmission of pathogens |
| US20100150941A1 (en) * | 2006-09-13 | 2010-06-17 | Dso National Laboratories | Hemagglutinin antibody and uses thereof |
| CN101553248B (zh) * | 2006-10-27 | 2012-09-19 | 贝林格尔.英格海姆维特梅迪卡有限公司 | 新的h5蛋白、其编码核酸、载体及它们的医药用途 |
| US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| US7981428B2 (en) | 2008-01-23 | 2011-07-19 | Academia Sinica | Flu vaccines and methods of use thereof |
| EP2563389B1 (en) | 2010-04-30 | 2015-07-08 | Temasek Life Sciences Laboratory Limited | Universal vaccine against h5n1 lineages |
| AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
| ES2689878T3 (es) | 2013-02-21 | 2018-11-16 | Boehringer Ingelheim Vetmedica Gmbh | Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento |
-
2012
- 2012-08-14 AR ARP120102979A patent/AR088028A1/es unknown
- 2012-08-15 AU AU2012296834A patent/AU2012296834A1/en not_active Abandoned
- 2012-08-15 JP JP2014525440A patent/JP2014527526A/ja active Pending
- 2012-08-15 US US14/238,796 patent/US20140199337A1/en not_active Abandoned
- 2012-08-15 CN CN201280045059.1A patent/CN104144699A/zh active Pending
- 2012-08-15 WO PCT/EP2012/065940 patent/WO2013024113A1/en not_active Ceased
- 2012-08-15 CA CA2845040A patent/CA2845040A1/en not_active Abandoned
- 2012-08-15 KR KR1020147006803A patent/KR101986071B1/ko active Active
- 2012-08-15 EP EP12746361.0A patent/EP2744514B1/en active Active
- 2012-08-15 BR BR112014003278A patent/BR112014003278A2/pt not_active IP Right Cessation
- 2012-08-15 ES ES12746361T patent/ES2765073T3/es active Active
- 2012-08-15 EA EA201400235A patent/EA201400235A1/ru unknown
- 2012-08-15 PH PH1/2014/500369A patent/PH12014500369A1/en unknown
- 2012-08-15 MX MX2014001754A patent/MX363464B/es unknown
-
2014
- 2014-02-27 CO CO14042269A patent/CO7020855A2/es unknown
-
2017
- 2017-07-28 US US15/662,358 patent/US10369211B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR101986071B1 (ko) | 2019-06-07 |
| KR20140090137A (ko) | 2014-07-16 |
| US20170348413A1 (en) | 2017-12-07 |
| JP2014527526A (ja) | 2014-10-16 |
| CN104144699A (zh) | 2014-11-12 |
| BR112014003278A2 (pt) | 2017-03-01 |
| MX363464B (es) | 2019-03-25 |
| MX2014001754A (es) | 2014-08-26 |
| AU2012296834A1 (en) | 2014-01-23 |
| EA201400235A1 (ru) | 2014-09-30 |
| CO7020855A2 (es) | 2014-08-11 |
| WO2013024113A1 (en) | 2013-02-21 |
| PH12014500369A1 (en) | 2014-04-14 |
| US20140199337A1 (en) | 2014-07-17 |
| CA2845040A1 (en) | 2013-02-21 |
| EP2744514A1 (en) | 2014-06-25 |
| EP2744514B1 (en) | 2019-10-16 |
| US10369211B2 (en) | 2019-08-06 |
| ES2765073T3 (es) | 2020-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088028A1 (es) | Proteinas h5, de h5n1 para un uso medicinal | |
| Vilas Boas et al. | Antiviral peptides as promising therapeutic drugs | |
| ES2869199T3 (es) | Sistemas de expresión | |
| JP2010508030A5 (enExample) | ||
| RU2009119597A (ru) | Новые белки н5, кодирующие их молекулы нуклеиновых кислот и векторы, и их применение в медицине | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| ES2673556T3 (es) | Vacunas para el VHS-2 | |
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| Lalani et al. | Antiviral peptides against Enterovirus A71 causing hand, foot and mouth disease | |
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| WO2010014567A3 (en) | Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof | |
| JP2012102105A5 (enExample) | ||
| JP2014527526A5 (enExample) | ||
| WO2022174768A1 (en) | Anti-viral peptides and compositions and methods of use thereof | |
| JP2020515283A5 (enExample) | ||
| ES2349153T3 (es) | Inhibidores del virus de la hepatitis c. | |
| EP4473122A2 (en) | Omicron coronavirus vaccine constructs and methods of making and using same | |
| RU2018112060A (ru) | Слитый белок | |
| US20230227848A1 (en) | Coronavirus vaccine constructs and methods of making and using same | |
| WO2011056802A1 (en) | Influenza virus recombinant proteins | |
| JP2019506840A5 (enExample) | ||
| CN108699113A (zh) | 肽及其作为抗病毒剂的用途 | |
| CN104311644B (zh) | 多肽、提高多肽稳定性的方法、药物组合物以及多肽在制备药物中的用途 | |
| WO2018038168A1 (ja) | ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬 | |
| Wang et al. | Monoclonal antibody, but not synthetic peptide, targeting the ectodomain of influenza B virus M2 proton channel has antiviral activity. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |